These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 33178201)

  • 1. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
    Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
    Front Immunol; 2020; 11():573326. PubMed ID: 33178201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?
    Mojsilovic SS; Mojsilovic S; Villar VH; Santibanez JF
    Anal Cell Pathol (Amst); 2021; 2021():5523055. PubMed ID: 34476174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer.
    Marcovecchio PM; Thomas G; Salek-Ardakani S
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of PD-1 in T cells for cancer immunotherapy.
    Yu X; Gao R; Li Y; Zeng C
    Eur J Pharmacol; 2020 Aug; 881():173240. PubMed ID: 32497624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
    Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Barriers to T Cell Function in Tumors.
    Sugiura A; Rathmell JC
    J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
    Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
    Front Immunol; 2021; 12():624725. PubMed ID: 34084160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell immunometabolism against cancer.
    Jiang S; Yan W
    Cancer Lett; 2016 Nov; 382(2):255-258. PubMed ID: 27664755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.
    Noman MZ; Hasmim M; Messai Y; Terry S; Kieda C; Janji B; Chouaib S
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C569-79. PubMed ID: 26310815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.
    Goruganthu MUL; Shanker A; Dikov MM; Carbone DP
    Front Immunol; 2020; 11():1958. PubMed ID: 32922403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
    Leone RD; Powell JD
    Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.